



## Bioactive Compounds in Chronic Diseases

Guest Editor:

**Prof. Dr. Vasso Apostolopoulos**

Institute for Health and Sport,  
Victoria University, Melbourne,  
VIC 3011, Australia

Deadline for manuscript  
submissions:

**closed (31 August 2023)**

### Message from the Guest Editor

Dear Colleagues,

Bioactive compounds can be derived from natural products, animal products, plants and can be synthetically produced. They have gained much attention in recent years as they have shown to be effective in a number of chronic and infectious diseases such as, cancer, cardiovascular disease, diabetes, autoimmune disorders and infectious diseases. In addition, their use can promote better health. As such vitamins, minerals, herbal, polyphenols, pre- and pro-biotics, natural products, nutritional therapies, cannabis therapies, have been shown to boost the immune system and as a result aids to manage and treat disease. This issue will focus on natural and bioactive treatments to overcome or manage chronic and infectious diseases, including in vitro, animal in vivo and human clinical studies.

Prof. Dr. Vasso Apostolopoulos  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)